Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.58 |
| ▸ | KIT | P10721 | 11/20 | 0.57 |
| ▸ | DDR1 | Q08345 | 11/20 | 0.57 |
| ▸ | BCR | P11274 | 7/20 | 0.57 |
| ▸ | DDR2 | Q16832 | 5/20 | 0.57 |
| ▸ | CSF1R | P07333 | 4/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | ABL2 | P42684 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9611109 | 0.92 | ABL1 (0.57) | ABL1KITDDR1BCRDDR2 | |
| SCHEMBL9611022 | 0.92 | ABL1 (0.68) | ABL1KITDDR1BCRDDR2 | |
| SCHEMBL9611007 | 0.88 | ABL1 (0.64) | ABL1KITDDR1BCRDDR2 | |
| SCHEMBL15473011 | 0.86 | ABL1 (0.53) | ABL1KITDDR1BCRDDR2 | |
| SCHEMBL9610802 | 0.86 | ABL1 (0.70) | ABL1KITDDR1BCRDDR2 | |
| SCHEMBL15061730 | 0.86 | ABL1 (0.68) | ABL1KITABL2MAPK14 | |
| SCHEMBL9611105 | 0.83 | ABL1 (0.69) | ABL1KITBCRCSF1RRET | |
| SCHEMBL15061755 | 0.81 | ABL1 (0.86) | ABL1KITDDR1BCRDDR2 | |
| SCHEMBL15871941 | 0.81 | ABL1 (0.69) | ABL1KITDDR1BCRDDR2 | |
| SCHEMBL15061726 | 0.81 | ABL1 (0.67) | ABL1RETABL2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8114874-B2 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885KIT 824/4885DDR1 4853/4885 |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885KIT 824/4885DDR1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.